Growth & profitability
- Revenue has grown 16.6% per year over the past 5 years.
- Operating margin has expanded, at -9.5% in the latest year.
TXG Financials 10x Genomics, Inc.
9 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
RevenueNet income
GrossOperatingNet
Free cash flow
CashTotal debt
OperatingInvestingFinancing
Key annual figures
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $643M | -$44M | 69.1% | -9.5% | $130M | — | $474M |
| 2024 | $611M | -$183M | 67.9% | -31.9% | -$6M | — | $344M |
| 2023 | $619M | -$255M | 66.2% | -42.9% | -$64M | — | $359M |
| 2022 | $516M | -$166M | 76.7% | -32.5% | -$165M | — | $227M |
| 2021 | $490M | -$58M | 84.9% | -10.7% | -$123M | — | $596M |
| 2020 | $299M | -$543M | 80.4% | -178.7% | -$255M | $0 | $689M |
| 2019 | $246M | -$31M | 75.2% | -12.4% | -$8M | $30M | $476M |
| 2018 | $146M | -$112M | 80.4% | -75.7% | -$83M | $30M | $70M |
| 2017 | — | -$19M | — | — | -$14M | — | $48M |
RevenueNet income
GrossOperatingNet
Free cash flow
CashTotal debt
OperatingInvestingFinancing
Key quarterly figures
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $151M | -$13M | 70.4% | -11.3% | $25M | — | $490M |
| Dec '25 | $166M | -$16M | 68.1% | -11.8% | $39M | — | $474M |
| Sep '25 | $149M | -$27M | 67.3% | -21.6% | $43M | — | $433M |
| Jun '25 | $173M | $35M | 72.3% | 17.4% | $16M | — | $398M |
| Mar '25 | $155M | -$34M | 68.1% | -25.4% | $32M | — | $377M |
| Dec '24 | $165M | -$49M | 67.2% | -30.2% | -$9M | — | $344M |
| Sep '24 | $152M | -$36M | 70.2% | -27.4% | $18M | — | $398M |
| Jun '24 | $153M | -$38M | 68.1% | -27.3% | $5M | — | $380M |
| Mar '24 | $141M | -$60M | 65.9% | -43.6% | -$19M | — | $356M |
| Dec '23 | $184M | -$49M | 62.9% | -30.0% | $22M | — | $359M |
| Sep '23 | $154M | -$93M | 62.2% | -61.7% | -$41M | — | $315M |
| Jun '23 | $147M | -$62M | 67.8% | -43.2% | -$37M | — | $331M |
| Mar '23 | $134M | -$51M | 73.3% | -38.7% | -$9M | — | $340M |
| Dec '22 | $156M | -$17M | 76.4% | -14.8% | -$26M | — | $227M |
| Sep '22 | $131M | -$42M | 76.8% | -30.5% | -$46M | — | $242M |
| Jun '22 | $115M | -$64M | 75.8% | -55.1% | -$44M | — | $282M |
| Mar '22 | $114M | -$42M | 77.7% | -36.5% | -$49M | — | $320M |
| Dec '21 | $144M | -$18M | 80.8% | -11.0% | -$22M | — | $596M |
| Sep '21 | $125M | -$17M | 80.4% | -12.7% | -$46M | — | $609M |
| Jun '21 | $116M | -$11M | 95.8% | -8.9% | -$11M | — | $649M |
Valuation over time
How the market has priced TXG against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
- The price-to-sales ratio has fallen from 13.9× (Mar '23) to 7.1× (Jun '26).
P/S
Frequently asked questions
Is TXG growing its revenue and profit?
Over the past 5 years, 10x Genomics, Inc.'s revenue has grown 16.6% per year. These are computed facts, not advice.
How much debt does TXG have?
As of FY2025, 10x Genomics, Inc. reported — of total debt against $474M of cash.
What is TXG's profit margin?
In FY2025, gross margin was 69.1%, operating margin -9.5%, and net margin -6.8%.
Where does this data come from?
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.